NCT04592666

Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer

Almonertinib Plus Pemetrexed and Carboplatin Versus Almonertinib Alone in Advanced NSCLC With EGFR T790M After First- or Second-generation TKIs Therapy: a Randomized, Controlled, Open-label, Phase 2 Study

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 226 (estimated)
• Sponsor: Fudan University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Almonertinib Plus Pemetrexed and Carboplatin Versus Almonertinib Alone in Advanced NSCLC With EGFR T790M After First- or Second-generation TKIs Therapy: a Randomized, Controlled, Open-label, Phase 2 Study

Conditions

• Lung Cancer, Non-small Cell
• EGFR T790M
• EGFR Gene Mutation

Interventions

Type	Name	Description
DRUG	Almonertinib	the standard therapy of single agent almonertinib
DRUG	Pemetrexed	standard dose
DRUG	Carboplatin	AUC=5

Timeline

• Start date: 2020-10-09
• Primary completion: 2021-12-31
• Completion: 2022-06-30
• First posted: 2020-10-19
• Last updated: 2020-10-19

Locations

1 site across 1 country: China